{
    "nct_id": "NCT06578247",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2024-08-29",
    "study_start_date": "2024-11-19",
    "study_completion_date": "",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Chemotherapy"
            },
            {
                "drug_name": "Drug: Placebo"
            },
            {
                "drug_name": "Drug: Quizartinib"
            }
        ]
    },
    "long_title": "Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia",
    "last_updated": "2025-09-10",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Daiichi Sankyo",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 700,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Key Inclusion Criteria:",
        "* Must be competent and able to comprehend, sign, and date an Ethics Committee (EC)- or Institutional Review Board (IRB)-approved Informed Consent Form (ICF) before performance of any trial-specific procedures or tests.",
        "* \u226518 years or the minimum legal adult age (whichever is greater) and 70 years (at Screening).",
        "* Newly diagnosed, morphologically documented primary AML based on the World Health Organization (WHO) 2016 classification (at Screening)",
        "* Eastern Cooperative Oncology Group (ECOG) performance status (at the time the participant signs their ICF) of 0-2.",
        "* Participant is receiving standard \"7+3\" induction chemotherapy regimen as specified in the protocol",
        "Exclude - Key Exclusion Criteria:",
        "Exclude - * Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or BCR-ABL positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).",
        "Exclude - * Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms or autoimmune/rheumatologic conditions.",
        "Exclude - * Diagnosis of AML secondary to myelodysplastic syndrome (MDS) or a myeloproliferative neoplasm (MPN) or MDS/MPNs including CMML, aCML, JMML and others.",
        "Exclude - * Participants with newly diagnosed AML with FLT3-ITD mutations (FLT3-ITD \\[+\\]) present at \u22655% VAF (or \u22650.05 SR) based on a validated FLT3 mutation assay.",
        "Exclude - * Prior treatment for AML, except for the following allowances:",
        "Exclude - 1. Leukapheresis;",
        "Exclude - 2. Treatment for hyperleukocytosis with hydroxyurea;",
        "Exclude - 3. Cranial radiotherapy for central nervous system (CNS) leukostasis;",
        "Exclude - 4. Prophylactic intrathecal chemotherapy;",
        "Exclude - 5. Growth factor/cytokine support."
    ],
    "short_title": "Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Daiichi Sankyo",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Arm A: Quizartinib + Chemotherapy",
                        "arm_internal_id": 0,
                        "arm_description": "Participants will receive quizartinib at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive quizartinib at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Quizartinib",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Chemotherapy",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Arm B: Placebo + Chemotherapy",
                        "arm_internal_id": 1,
                        "arm_description": "Participants will receive placebo at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive placebo at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Placebo",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Chemotherapy",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Arm C: Quizartinib + Chemotherapy then Placebo Maintenance",
                        "arm_internal_id": 2,
                        "arm_description": "Participants will receive quizartinib at 60 mg/day orally once daily for 14 days starting after the completion of chemotherapy in Induction and Consolidation Phase. In the Maintenance Phase, participants will receive placebo at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Quizartinib",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Placebo",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Chemotherapy",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "disease_status": [
                                        "Untreated"
                                    ],
                                    "oncotree_primary_diagnosis": "Lymphoid Neoplasm"
                                }
                            },
                            {
                                "and": [
                                    {
                                        "or": []
                                    },
                                    {
                                        "and": [
                                            {
                                                "genomic": {
                                                    "hugo_symbol": "FLT3",
                                                    "variant_category": "!Mutation"
                                                }
                                            }
                                        ]
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        ]
    }
}